GO:0044774 mitotic DNA integrity checkpoint signaling: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0044774 mitotic DNA integrity checkpoint signaling is a biological process that monitors DNA structure during mitosis and controls cell cycle progression in response to DNA damage or replication defects.
• The pathway is also known as the decatenation checkpoint or topoisomerase II checkpoint, reflecting its role in sensing DNA topology and catenation states.
• Core protein kinases such as ATM, ATR, CHEK1, CHEK2, and PLK1 transduce signals that delay mitotic progression until DNA integrity is restored [1,4].
• Dysregulation of this checkpoint is linked to chromosomal instability, aneuploidy, and cancer, making it a target for therapeutic intervention [2,8].
• Experimental models including CRISPR knockout, point mutation, and knock-in cell lines are essential to dissect the pathway's molecular players [1,8].
• The checkpoint operates in diverse organisms, from trypanosomes to plants and mammals, underscoring its evolutionary conservation [5,7].
Description
The mitotic DNA integrity checkpoint signaling pathway, annotated as GO:0044774, is a critical biological process that ensures genomic stability by monitoring DNA structure during mitosis. This signaling cascade detects DNA damage, defects in DNA structure, or incomplete DNA replication and delays cell cycle progression until repair or resolution occurs [1,8]. The term is synonymous with the decatenation checkpoint and topoisomerase II checkpoint, highlighting its role in sensing DNA topology and catenation states. Understanding this pathway is fundamental for researchers studying cell cycle regulation, genome maintenance, and cancer biology, as its dysfunction can lead to chromosomal instability and tumorigenesis [2,8]. The checkpoint involves a complex network of sensor kinases, transducers, and effectors that coordinate mitotic progression with DNA integrity [4,8]. This article provides a comprehensive overview of the pathway's mechanism, key genes, disease associations, and research methodologies, with a focus on CRISPR-based models for functional studies.
mitotic DNA integrity checkpoint signaling At A Glance
| GO ID | GO:0044774 |
|---|---|
| GO term | mitotic DNA integrity checkpoint signaling |
| Ontology | biological_process |
| Synonym | mitotic DNA integrity checkpoint; decatenation checkpoint; topoisomerase II checkpoint; topo II checkpoint |
| Major function | Monitors DNA integrity during mitosis and delays cell cycle progression in response to DNA damage or replication defects |
| Related pathways | DNA damage response, cell cycle checkpoint, mitotic regulation |
| Key kinases | ATM, ATR, CHEK1, CHEK2, PLK1 |
| Disease relevance | Cancer, chromosomal instability, aneuploidy |
| Evolutionary conservation | Present in trypanosomes, plants, and mammals |
What Is GO:0044774?
GO:0044774 mitotic DNA integrity checkpoint signaling is defined as a signaling process that controls cell cycle progression in response to changes in DNA structure by monitoring the integrity of the DNA during mitosis. The checkpoint begins with the detection of DNA damage, defects in DNA structure, or DNA replication issues, and ends with signal transduction that ultimately delays or arrests mitosis until the damage is resolved.
Why Is mitotic DNA integrity checkpoint signaling Important in Cell Biology?
The mitotic DNA integrity checkpoint is essential for maintaining genomic stability by preventing cells with damaged or incompletely replicated DNA from progressing through mitosis [1,8]. Its dysfunction is a hallmark of many cancers, where chromosomal instability and aneuploidy drive tumor progression and drug resistance. Understanding this pathway provides insights into fundamental cell cycle control and offers potential targets for cancer therapy, particularly through the development of checkpoint kinase inhibitors. Moreover, the pathway's conservation across species makes it a valuable model for studying DNA damage responses in diverse biological contexts [5,7].
• Prevents transmission of damaged DNA to daughter cells, safeguarding genomic integrity.
• Dysregulation leads to chromosomal instability, a common feature of solid tumors and leukemias.
• Checkpoint kinases such as CHEK1 are promising targets for cancer therapeutics.
• Plays a role in oocyte activation and early embryonic development.
• Involved in DNA repair complex assembly through proteins like hPso4/hPrp19.
• Operates in plants to coordinate DNA damage recognition with mitotic progression.
• Provides a mechanism for kinetochore-based, ATM/ATR-independent DNA damage surveillance in trypanosomes.
• Serves as a model for understanding how epigenetic changes influence chromosomal instability.
• Enables researchers to study cell cycle checkpoints using CRISPR-engineered cell models [1,8].
• Contributes to the development of targeted therapies that exploit checkpoint vulnerabilities in cancer.
What Happens During mitotic DNA integrity checkpoint signaling?
DNA Damage Detection
In simple terms: The cell senses that something is wrong with its DNA during mitosis.
The checkpoint begins with the detection of DNA damage, defects in DNA structure, or incomplete DNA replication during mitosis. Sensor proteins recognize abnormal DNA structures, such as double-strand breaks or catenated DNA, and initiate a signaling cascade. In trypanosomes, a kinetochore-based, ATM/ATR-independent mechanism monitors DNA damage, demonstrating evolutionary diversity in detection strategies. In plants, mechanistic insights into DNA damage recognition have revealed conserved and unique features of checkpoint control.
Signal Transduction by Checkpoint Kinases
In simple terms: A relay of kinases amplifies the alarm signal to halt the cell cycle.
Once DNA damage is detected, sensor kinases such as ATM and ATR activate downstream transducer kinases, including CHEK1 and CHEK2. These kinases phosphorylate effector proteins that ultimately inhibit the mitotic machinery, delaying progression to anaphase. CHEK1 is a critical component of the DNA damage response network, and its inhibition can abrogate checkpoint arrest. The signaling cascade involves complex interactions with DNA repair proteins, such as hPso4/hPrp19, which are integral to checkpoint complexes.
Cell Cycle Arrest and Repair
In simple terms: The cell pauses mitosis to fix the DNA before dividing.
Activated checkpoint kinases lead to cell cycle arrest at the G2/M transition or during mitosis, providing time for DNA repair [1,8]. This arrest is mediated by inhibition of CDC25 phosphatases and activation of WEE1 kinase, which keep CDK1 in an inactive state. If repair is successful, the checkpoint is silenced and mitosis resumes; if damage is irreparable, the cell may undergo apoptosis or senescence. The decatenation checkpoint specifically monitors DNA topology and delays anaphase until catenated DNA is resolved.
Resolution and Checkpoint Silencing
In simple terms: Once DNA is fixed, the brake is released and mitosis continues.
After DNA repair or resolution of topological stress, the checkpoint signal is terminated through dephosphorylation and degradation of checkpoint proteins. This allows activation of the anaphase-promoting complex/cyclosome (APC/C) and progression to anaphase. Proper silencing is crucial to prevent prolonged arrest that could lead to cell death or genomic instability. The mechanisms of checkpoint silencing involve phosphatases such as PP2A and the degradation of CHEK1.
Key Genes Involved in GO:0044774 mitotic DNA integrity checkpoint signaling
The following genes and proteins are central to the mitotic DNA integrity checkpoint signaling pathway, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ATM | Sensor kinase that detects DNA double-strand breaks and initiates checkpoint signaling | Mutations cause ataxia-telangiectasia; target for radiosensitization |
| ATR | Sensor kinase responding to replication stress and DNA damage | Essential for checkpoint activation; studied in cancer therapy |
| CHEK1 | Effector kinase that phosphorylates CDC25 and WEE1 to enforce cell cycle arrest | Inhibitors in clinical trials for cancer; key node in DNA damage response |
| CHEK2 | Effector kinase involved in G2/M arrest and DNA repair | Germline mutations linked to breast and prostate cancer |
| PLK1 | Polo-like kinase regulating mitotic progression and checkpoint recovery | Overexpressed in many cancers; target for inhibitors |
| WEE1 | Kinase that inhibits CDK1 to maintain G2/M arrest | Inhibitor AZD1775 in clinical trials; synthetic lethality with p53 mutations |
| CDC25C | Phosphatase that activates CDK1; inhibited by checkpoint kinases | Deregulated in cancers; biomarker for checkpoint function |
| TP53 | Tumor suppressor that can induce cell cycle arrest or apoptosis upon DNA damage | Most commonly mutated gene in cancer; influences checkpoint outcomes |
| TOP2A | Topoisomerase II that resolves DNA catenation; monitored by decatenation checkpoint | Target of etoposide; mutations cause chemoresistance |
| hPso4/hPrp19 | Component of DNA repair and checkpoint complexes | Involved in splicing and DNA damage response; potential therapeutic target |
| MDC1 | Mediator of DNA damage checkpoint signaling | Required for ATM activation and checkpoint maintenance |
| RAD51 | RecA homolog involved in homologous recombination repair | Overexpressed in cancers; target for synthetic lethality |
| BRCA1 | Tumor suppressor involved in DNA repair and checkpoint control | Mutations cause hereditary breast/ovarian cancer; PARP inhibitor target |
| BRCA2 | Tumor suppressor involved in homologous recombination | Mutations cause Fanconi anemia and breast cancer |
| Aurora A | Kinase regulating mitotic entry and spindle assembly | Overexpressed in cancers; target for inhibitors |
| Aurora B | Chromosomal passenger kinase regulating chromosome segregation and checkpoint | Involved in error correction; inhibitor targets |
| BUB1 | Spindle assembly checkpoint kinase | Mutated in colorectal cancer; crosstalk with DNA integrity checkpoint |
| MAD2 | Spindle assembly checkpoint protein | Deregulated in aneuploid tumors |
How Is mitotic DNA integrity checkpoint signaling Regulated?
The mitotic DNA integrity checkpoint is regulated at multiple levels, including phosphorylation, ubiquitination, and protein-protein interactions [1,4]. Checkpoint kinases such as ATM and ATR are activated by autophosphorylation and recruitment to DNA damage sites via mediator proteins like MDC1. Phosphatases including PP2A and WIP1 reverse checkpoint signaling to allow cell cycle resumption after repair. The ubiquitin-proteasome system degrades key checkpoint proteins, such as CHEK1, to terminate the signal. Additionally, epigenetic modifications influence chromosomal instability and checkpoint gene expression, as reviewed in the context of cancer. In plants, mechanistic studies have revealed hormone-dependent regulation of DNA damage recognition and checkpoint control.
mitotic DNA integrity checkpoint signaling and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TP53 | Li-Fraumeni syndrome, diverse cancers | Knockout and point-mutation cell lines to study checkpoint bypass |
| ATM | Ataxia-telangiectasia, increased cancer risk | Knockout models to assess radiosensitivity and checkpoint defects |
| CHEK1 | Cancer, chemoresistance | Point mutation (kinase-dead) and knockout for inhibitor studies |
| BRCA1 | Hereditary breast and ovarian cancer | Knock-in of patient mutations to study checkpoint and repair |
| TOP2A | Cancer, chemoresistance to etoposide | Overexpression and knockout to dissect decatenation checkpoint |
Cancer and Chromosomal Instability
Dysregulation of the mitotic DNA integrity checkpoint is a major driver of chromosomal instability (CIN), a hallmark of many cancers. Mutations in checkpoint genes such as TP53, ATM, and CHEK2 lead to defective cell cycle arrest and accumulation of DNA damage, promoting tumorigenesis [1,4]. Overexpression of PLK1 and Aurora kinases is frequently observed in solid tumors and correlates with poor prognosis. Targeting checkpoint kinases with small molecule inhibitors, such as CHEK1 inhibitors, is an active area of clinical research. Epigenetic alterations that affect checkpoint gene expression further contribute to CIN and cancer progression.
Neurodegeneration and Aging
Defects in DNA damage response pathways, including the mitotic DNA integrity checkpoint, have been implicated in neurodegenerative diseases and premature aging. Neurons are particularly vulnerable to DNA damage due to their post-mitotic nature, but aberrant checkpoint activation in dividing neural progenitors can lead to developmental defects. Proteins such as hPso4/hPrp19, which link DNA repair and checkpoint signaling, are associated with neurodegeneration when mutated. Understanding these connections may reveal therapeutic targets for neuroprotection.
Reproductive Disorders
The checkpoint for DNA integrity at the first mitosis after oocyte activation is critical for early embryonic development. Errors in this checkpoint can lead to aneuploidy in embryos, causing miscarriage or developmental disorders. Studies in model organisms have shown that the decatenation checkpoint ensures proper chromosome segregation during the first mitotic division. This has implications for assisted reproductive technologies and understanding infertility.
From mitotic DNA integrity checkpoint signaling-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate the decatenation checkpoint? | CRISPR knockout cell line followed by mitotic arrest assays |
| What is the role of a specific phosphorylation site in CHEK1? | Point mutation knock-in (e.g., S317A) to abrogate phosphorylation |
| How does a cancer-associated mutation affect checkpoint function? | Knock-in of the mutation into a wild-type cell line |
| Where does protein Y localize during checkpoint activation? | Tagged knock-in (e.g., GFP) for live-cell imaging |
| Does overexpression of PLK1 bypass checkpoint arrest? | Overexpression cell line using inducible promoters |
| Can a drug inhibit checkpoint kinase Z? | Knockout of the kinase to validate target engagement |
How to Study the mitotic DNA integrity checkpoint signaling Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screens | Loss-of-function phenotypes for all genes | Identify novel checkpoint regulators |
| Live-cell imaging | Mitotic duration and chromosome dynamics | Assess decatenation checkpoint activity |
| Phosphoproteomics | Global phosphorylation changes | Map kinase substrates and signaling networks |
| Flow cytometry | Cell cycle distribution and mitotic index | Quantify checkpoint arrest in mutant cells |
| Immunofluorescence | Localization of checkpoint proteins | Study recruitment to DNA damage sites |
| Western blot | Protein expression and phosphorylation | Validate kinase activation and target engagement |
| Comet assay | DNA damage levels | Measure genotoxicity and repair capacity |
| RNA-seq | Transcriptional changes | Identify gene expression signatures of checkpoint activation |
CRISPR-Based Genetic Screens
Genome-wide CRISPR knockout screens can identify novel genes required for the mitotic DNA integrity checkpoint. By treating cells with checkpoint-activating agents (e.g., etoposide or nocodazole) and selecting for survivors, researchers can uncover genes whose loss bypasses checkpoint arrest. These screens have revealed components of the decatenation checkpoint and DNA damage response. Bioinformatics analysis of screen data, such as pathway enrichment, helps prioritize hits for validation.
Live-Cell Imaging and Mitotic Timing
Live-cell imaging using fluorescently tagged proteins (e.g., histone H2B-GFP, GFP-CHEK1) allows real-time monitoring of mitotic progression and checkpoint activation. Time-lapse microscopy can quantify the duration of mitosis and detect delays indicative of checkpoint engagement. This method is particularly useful for studying the decatenation checkpoint, which operates during prophase to metaphase.
Phosphoproteomics and Signaling Analysis
Mass spectrometry-based phosphoproteomics can identify substrates of checkpoint kinases such as ATM, ATR, and CHEK1. By comparing phosphoproteomes of wild-type and knockout cells treated with DNA damage, researchers can map signaling networks. This approach has revealed crosstalk between the checkpoint and DNA repair machinery.
Flow Cytometry and Cell Cycle Analysis
Flow cytometry using DNA dyes (e.g., propidium iodide) and phospho-histone H3 antibodies can quantify cell cycle distribution and mitotic arrest. This method is used to assess checkpoint function in knockout or mutant cell lines. Combined with EdU incorporation, it can distinguish between G2 arrest and mitotic delay.
How CRISPR Can Be Used to Study GO:0044774 mitotic DNA integrity checkpoint signaling
Knockout
CRISPR knockout of checkpoint genes such as ATM, ATR, CHEK1, or PLK1 is used to abrogate pathway function and study downstream effects [1,4]. Knockout cell lines can be challenged with DNA-damaging agents to assess whether the checkpoint is required for cell cycle arrest. These models are also valuable for identifying synthetic lethal interactions, such as CHEK1 knockout in p53-deficient cells.
Point Mutation
Point mutations can be introduced to study specific phosphorylation sites or catalytic residues in checkpoint kinases. For example, a kinase-dead mutant of CHEK1 can be knocked into the endogenous locus to dissect its role in checkpoint signaling without affecting protein stability. Such models are crucial for understanding the precise molecular mechanisms of checkpoint control.
Knock-in
Knock-in of disease-associated mutations, such as those in TP53 or BRCA1, allows researchers to study their impact on the mitotic DNA integrity checkpoint in an isogenic background. Tagged knock-in (e.g., GFP or HA) enables visualization and immunoprecipitation of checkpoint proteins at endogenous levels. These models provide physiologically relevant insights into checkpoint dysfunction in cancer.
Overexpression
Overexpression of checkpoint kinases like PLK1 or Aurora A can be achieved via CRISPR-mediated knock-in of a strong promoter or lentiviral transduction [1,8]. Overexpression models are used to study how elevated kinase levels contribute to checkpoint bypass and chromosomal instability. They also serve as tools for drug screening to identify inhibitors that target overactive checkpoint pathways.
How EDITGENE Supports mitotic DNA integrity checkpoint signaling Research
Researchers studying mitotic DNA integrity checkpoint signaling-related genes often need to determine whether a candidate gene is causally involved in the pathway or merely correlated with its activation. This requires precise genetic manipulation to create loss-of-function, gain-of-function, or patient-specific mutations in relevant cell models. EDITGENE provides a comprehensive suite of CRISPR-based services to support such functional studies, from knockout to knock-in and library screening.
Contact EDITGENE today to design your custom CRISPR model for mitotic DNA integrity checkpoint signaling research.
Frequently Asked Questions About mitotic DNA integrity checkpoint signaling
What is mitotic DNA integrity checkpoint signaling?
It is a biological process (GO:0044774) that monitors DNA structure during mitosis and delays cell cycle progression in response to DNA damage or replication defects.
What genes are involved in the mitotic DNA integrity checkpoint?
Key genes include ATM, ATR, CHEK1, CHEK2, PLK1, WEE1, CDC25C, TP53, TOP2A, and BRCA1, among others [1,4,8].
How is the decatenation checkpoint related to GO:0044774?
The decatenation checkpoint is a synonym for the mitotic DNA integrity checkpoint, specifically monitoring DNA catenation states during mitosis.
What diseases are associated with defects in this checkpoint?
Defects are linked to cancer, chromosomal instability, neurodegeneration, and reproductive disorders [2,3,8].
Which kinases are central to mitotic DNA integrity checkpoint signaling?
ATM, ATR, CHEK1, CHEK2, and PLK1 are core kinases that transduce the checkpoint signal [1,4].
How can CRISPR be used to study this checkpoint?
CRISPR knockout, point mutation, knock-in, and overexpression models allow functional dissection of checkpoint genes in cell lines [1,4,8].
What methods are used to measure checkpoint activity?
Common methods include live-cell imaging, flow cytometry, phosphoproteomics, and CRISPR screens [1,4,8].
Is the mitotic DNA integrity checkpoint conserved across species?
Yes, it is present in organisms ranging from trypanosomes to plants and mammals [5,7].
What is the role of topoisomerase II in this checkpoint?
Topoisomerase II resolves DNA catenation, and its activity is monitored by the decatenation checkpoint to ensure proper chromosome segregation.
How does the checkpoint contribute to cancer therapy resistance?
Cancer cells with defective checkpoints may rely on alternative pathways, and checkpoint inhibitors can sensitize them to DNA-damaging agents.
Conclusion
The mitotic DNA integrity checkpoint signaling pathway (GO:0044774) is a fundamental mechanism that safeguards genomic stability by coordinating mitotic progression with DNA repair [1,8]. Its dysregulation is implicated in cancer, neurodegeneration, and reproductive disorders, making it a compelling target for therapeutic intervention [2,4]. Advances in CRISPR-based models and high-throughput screening are accelerating our understanding of this pathway and its components [1,4]. EDITGENE's comprehensive services empower researchers to dissect the molecular details of this checkpoint and translate findings into clinical applications.
References
- 1. Rasteh AM et al.. 2024. Pan-cancer genetic profiles of mitotic DNA integrity checkpoint protein kinases.. Cancer Biomark 41(3-4):CBM240119 PMID: 40095483
- 2. Vitale I et al.. 2026. Epigenetic drivers of chromosomal instability.. Trends Cancer 12(2):95-98 PMID: 41339187
- 3. Liu L et al.. 2002. Checkpoint for DNA integrity at the first mitosis after oocyte activation.. Mol Reprod Dev 62(2):277-88 PMID: 11984839
- 4. Dai Y et al.. 2010. New insights into checkpoint kinase 1 in the DNA damage response signaling network.. Clin Cancer Res 16(2):376-83 PMID: 20068082
- 5. Zhou Q et al.. 2019. A kinetochore-based ATM/ATR-independent DNA damage checkpoint maintains genomic integrity in trypanosomes.. Nucleic Acids Res 47(15):7973-7988 PMID: 31147720
- 6. Mahajan K. 2016. hPso4/hPrp19: a critical component of DNA repair and DNA damage checkpoint complexes.. Oncogene 35(18):2279-86 PMID: 26364595
- 7. Herbst J et al.. 2024. Mechanistic insights into DNA damage recognition and checkpoint control in plants.. Nat Plants 10(4):539-550 PMID: 38503962
- 8. Petsalaki E et al.. 2020. DNA damage response proteins regulating mitotic cell division: double agents preserving genome stability.. FEBS J 287(9):1700-1721 PMID: 32027459
